US Stock MarketDetailed Quotes

ALT Altimmune

Watchlist
  • 9.030
  • +0.440+5.12%
Close Dec 13 16:00 ET
  • 8.920
  • -0.110-1.22%
Post 19:52 ET
642.26MMarket Cap-5.75P/E (TTM)

About Altimmune Company

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Company Profile

SymbolALT
Company NameAltimmune
Listing DateOct 6, 2005
Founded1997
CEODr. Vipin K. Garg, PhD
MarketNASDAQ
Employees59
Fiscal Year Ends12-31
Address910 Clopper Road,Suite 201S
CityGaithersburg
ProvinceMaryland
CountryUnited States of America
Zip Code20878
Phone1-240-654-1450

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Vipin K. Garg, PhD
  • Director, President and Chief Executive Officer
  • 5.48M
  • Dr. M. Scott Harris, M.D.
  • Chief Medical Officer
  • 2.24M
  • Dr. M. Scot Roberts, PhD
  • Chief Scientific Officer
  • --
  • Gregory L. Weaver
  • Chief Financial Officer and Principal Accounting Officer
  • --
  • Raymond M. Jordt, M.B.A.
  • Chief Business Officer
  • 2.94M
  • Dr. Mitchel Sayare,PhD
  • Chairman of the Board
  • 119.68K
  • Wayne Pisano
  • Independent Director
  • 108.68K
  • Dr. Catherine Angell Sohn, Pharm.D.
  • Independent Director
  • 273.47K
  • Dr. Klaus O. Schafer, M.D.,M.P.H.
  • Independent Director
  • 104.68K
  • Dr. Diane K. Jorkasky, M.D.
  • Independent Director
  • 95.68K
  • Philip L. Hodges
  • Independent Director
  • 115.68K
  • John M. Gill
  • Independent Director
  • 103.68K
  • Andrew Shutterly, M.S.
  • Corporate Controller
  • --
Heat List
US
Overall
Symbol
Price
% Chg

No Data